In 1998 it was first showed that intravenous Intralipid could prevent or improve resuscitation from cardiovascular collapse by severe bupivacaine overdose in rats. Since then published examples now include toxicities ...In 1998 it was first showed that intravenous Intralipid could prevent or improve resuscitation from cardiovascular collapse by severe bupivacaine overdose in rats. Since then published examples now include toxicities related to verapamil, diltiazem, amlodipine, quetiapine and sertraline, haldoperidol, lamotrigine, olanzapine, propranolol, atenolol, nevibolol, doxepin, dosulepin, imipramine, amitriptyline, glyosphate herbicide, flecainide, venlafaxine, moxidectin, and others. Amniotic fluid embolism (AFE) is a rare but potentially catastrophic obstetric emergency. Despite earlier recognition and aggressive treatment, morbidity and mortality rates remain high. An estimated 5% - 15% of all maternal deaths in Western countries are due to AFE. The pathophysiology of AFE is not completely understood. AFE most commonly occurs during labor, delivery, or the immediate postpartum period. However, it has been reported to occur up to 48 h postpartum. Pulmonary hypertension and right heart strain/failure may be the result of physical amniotic fluid debris in the pulmonary vasculature or, perhaps more likely, result from circulating pulmonary vasoconstrictive mediators. Therapy with Intralipid in male rats resulted in 100% survival and prevented Pulmonary arterial hypertension-induced right ventricular failure by preserving right ventricular pressure and right ventricular ejection fraction and preventing right ventricular hypertrophy and lung remodeling. In preexisting severe Pulmonary arterial hypertension, Intralipid attenu-ated most lung and right ventricular abnormalities. The beneficial effects of Intralipid in Pulmonary arterial hypertension seem to result from the interplay of various factors, among which preservation and/or stimulation of angiogenesis, suppression and/or reversal of inflammation, fibrosis and hypertrophy, in both lung and right ventricular, appear to be major contributors. In conclusion, Intralipid not only prevents the development of Pulmonary arterial hypertension and right ventricular failure but also rescues preexisting severe Pulmonary arterial hypertension. Intralipid treatment is a new treatment for AFE (amniotic fluid embolism) which was never suggested before. Animal studies should be done in order to evaluate this new treatment modality.展开更多
A new proposal for spinal cord and brain treatment and protection due to injuries and diseases is made herein. It is composed of two 20G nylon catheters with 6 lateral holes arranged circumferentially within 3 cm from...A new proposal for spinal cord and brain treatment and protection due to injuries and diseases is made herein. It is composed of two 20G nylon catheters with 6 lateral holes arranged circumferentially within 3 cm from the tip and a closed end. One catheter is inserted into the epidural space and the other catheter is inserted into the spinal space in two different lumbar interspaces using an 18G Tuohy needle 90 mm. The epidural catheter is used for cooled saline injection and infusion. The spinal catheter is used for Intralipid spinal injections and CSF aspiration. The proposal is based on the current studies on spinal cord cooling and CSF aspiration as well as on the Intralipid resuscitation properties and lipid brain protection. A study is needed to evaluate the clinical value of this combined approach.展开更多
<strong>Aim: </strong><span style="font-family:""><span style="font-family:Verdana;">To evaluate the safety and efficacy of intralipid infusion in addition to other lin...<strong>Aim: </strong><span style="font-family:""><span style="font-family:Verdana;">To evaluate the safety and efficacy of intralipid infusion in addition to other lines of treatment in reduction of complications caused by antiphospholipid antibody syndrome. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> This study was held in the period from June 1, 2016, to December 1, 2019. This study was conducted in the Department of Obstetrics and Gynecology, Tanta University on patients attending the antenatal care clinic and also on patients attending the researcher’s private clinics for antenatal care, 105 patients were enrolled after application of strict inclusion and exclusion criteria. They were randomized into 2 groups. In group A (study group 1) the patients received in addition to the conventional basic treatment of APS, intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline IV and to be repeated every 2 weeks. In group B (control group 2) the patients received the conventional basic treatment of APS. The outcome measures were the incidence of pregnancy complications of APS namely fetal loss, premature delivery, IUGR and preeclampsia. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">49 patients were enrolled in the study group, and 48 patients were enrolled in the control group, after exclusion of the skipped cases. The demographic data and the gestational age at the beginning of the study show insignificant differences. There were insignificant differences as regard the gestational age at which the pregnancy was terminated and fetal birth weight in patients with positive ACL test, positive LA test and positive B2 however the mean gestational age at which pregnancy was terminated was higher in study group. Also, there was insignificant difference as regards no of patients who complicated with abortion or who completed to full term. But had significant decrease number of case who complicated with preeclampsia (8, 21 patients in study and control group respectively). </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Intralipid infusion is a promising treatment option for control and prevention of problems caused by antiphospholipid antibody syndrome.</span></span>展开更多
Background: Despite advances in revascularization and thrombolytic therapy, the outcome of patients after acute myocardial infarction (MI) could be complicated by ischemia reperfusion injury (IRI) and subsequent ventr...Background: Despite advances in revascularization and thrombolytic therapy, the outcome of patients after acute myocardial infarction (MI) could be complicated by ischemia reperfusion injury (IRI) and subsequent ventricular remodeling. Inflammation plays a central role in IRI. Intralipid<sup>®</sup> has been shown to reduce infarct size after IRI, but its effects on myocardial inflammation have not been addressed. The goal of this study is to investigate the effects of Intralipid<sup>®</sup> on in-situ myocardial inflammation and to better characterize its cardio-protective effects. Methods and Results: Cellular MRI was used to evaluate myocardial inflammation of iron-oxide-labeled macrophage infiltration. Cardiac MRI was used to evaluate global and regional ventricular wall motion, as well as myocardial perfusion and infarction in a rat model. Our results show that the Intralipid<sup>®</sup> treatment following IRI can preserve global and regional ventricular wall motion, and reduce the infarct size. The In-tralipid<sup>®</sup>-treated rats exhibit reduced myocardial macrophage infiltration, indicating reduced in-situ myocardial inflammation. Conclusions: Our results indicate that the Intralipid<sup>®</sup> treatment can protect the heart against IRI and can specifically reduce in-situ myocardial inflammation. Additional study is needed to assess if treatment using Intralipid<sup>®</sup> after LAD occlusion could improve the recovery of patients suffering from a heart attack and also reduce future development of heart failure.展开更多
Background The commonly used method so far for formulating hyperlipidemia animal models is to feed the animals with a high fat diet. Owning to influences of animal feeding, dosage and cycle, feeding with a high fat di...Background The commonly used method so far for formulating hyperlipidemia animal models is to feed the animals with a high fat diet. Owning to influences of animal feeding, dosage and cycle, feeding with a high fat diet has resulted in an unstable quality. It is unknown whether gastric perfusion of intralipid can establish a better hyperlipidemia model in rabbits. Methods Twenty rabbits were randomly selected and subjected to gastric intralipid perfusion for consecutive 2 weeks or to feed with common high cholesterol feed for 4 weeks. The levels of blood serum total cholesterol （TC）, triglyceride （TG）, apolipoprotein A1 （APOA1）, APOB, blood plasma thromboxane B2 （TXB2）, 6-Keto-prostaglandin F1α （6-Keto-PGF1α）, endotheline （ET）, erythrocyte membrane cholesterol （M-Tc）, membrane fluidity （M-Flu）, erythrocyte malondialdehyde （E-MDA）, erythrocyte superoxide dismutase （E-SOD） before and after the experiment. In the end of the experiment, the aortae were removed from all the animals for light and electron microscopic examinations. Results The results showed that in both groups, the levels of blood serum TC, TG, APOB, blood plasma TXB2, ET, erythrocyte M-Flu and E-MDA were significantly increased. Blood serum APOA1, blood plasma 6-Keto-PGF1α and E-SOD were significantly decreased. But, erythrocyte M-TC had no significantly changed. The indexes of the two groups were no obvious difference before and after the experiment. Light and electron microscopic examination showed that there were early changes of early atherosclosis in the two groups of animal, in accordance with the characteristics of experimental animal hyperlipidemia. Conclusion The results suggest that gastric perfusion of intralipid can produce hyperlipidemia in rabbits faster than the commonly used model developed by feeding high cholesterol diet.展开更多
文摘In 1998 it was first showed that intravenous Intralipid could prevent or improve resuscitation from cardiovascular collapse by severe bupivacaine overdose in rats. Since then published examples now include toxicities related to verapamil, diltiazem, amlodipine, quetiapine and sertraline, haldoperidol, lamotrigine, olanzapine, propranolol, atenolol, nevibolol, doxepin, dosulepin, imipramine, amitriptyline, glyosphate herbicide, flecainide, venlafaxine, moxidectin, and others. Amniotic fluid embolism (AFE) is a rare but potentially catastrophic obstetric emergency. Despite earlier recognition and aggressive treatment, morbidity and mortality rates remain high. An estimated 5% - 15% of all maternal deaths in Western countries are due to AFE. The pathophysiology of AFE is not completely understood. AFE most commonly occurs during labor, delivery, or the immediate postpartum period. However, it has been reported to occur up to 48 h postpartum. Pulmonary hypertension and right heart strain/failure may be the result of physical amniotic fluid debris in the pulmonary vasculature or, perhaps more likely, result from circulating pulmonary vasoconstrictive mediators. Therapy with Intralipid in male rats resulted in 100% survival and prevented Pulmonary arterial hypertension-induced right ventricular failure by preserving right ventricular pressure and right ventricular ejection fraction and preventing right ventricular hypertrophy and lung remodeling. In preexisting severe Pulmonary arterial hypertension, Intralipid attenu-ated most lung and right ventricular abnormalities. The beneficial effects of Intralipid in Pulmonary arterial hypertension seem to result from the interplay of various factors, among which preservation and/or stimulation of angiogenesis, suppression and/or reversal of inflammation, fibrosis and hypertrophy, in both lung and right ventricular, appear to be major contributors. In conclusion, Intralipid not only prevents the development of Pulmonary arterial hypertension and right ventricular failure but also rescues preexisting severe Pulmonary arterial hypertension. Intralipid treatment is a new treatment for AFE (amniotic fluid embolism) which was never suggested before. Animal studies should be done in order to evaluate this new treatment modality.
文摘A new proposal for spinal cord and brain treatment and protection due to injuries and diseases is made herein. It is composed of two 20G nylon catheters with 6 lateral holes arranged circumferentially within 3 cm from the tip and a closed end. One catheter is inserted into the epidural space and the other catheter is inserted into the spinal space in two different lumbar interspaces using an 18G Tuohy needle 90 mm. The epidural catheter is used for cooled saline injection and infusion. The spinal catheter is used for Intralipid spinal injections and CSF aspiration. The proposal is based on the current studies on spinal cord cooling and CSF aspiration as well as on the Intralipid resuscitation properties and lipid brain protection. A study is needed to evaluate the clinical value of this combined approach.
文摘<strong>Aim: </strong><span style="font-family:""><span style="font-family:Verdana;">To evaluate the safety and efficacy of intralipid infusion in addition to other lines of treatment in reduction of complications caused by antiphospholipid antibody syndrome. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> This study was held in the period from June 1, 2016, to December 1, 2019. This study was conducted in the Department of Obstetrics and Gynecology, Tanta University on patients attending the antenatal care clinic and also on patients attending the researcher’s private clinics for antenatal care, 105 patients were enrolled after application of strict inclusion and exclusion criteria. They were randomized into 2 groups. In group A (study group 1) the patients received in addition to the conventional basic treatment of APS, intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline IV and to be repeated every 2 weeks. In group B (control group 2) the patients received the conventional basic treatment of APS. The outcome measures were the incidence of pregnancy complications of APS namely fetal loss, premature delivery, IUGR and preeclampsia. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">49 patients were enrolled in the study group, and 48 patients were enrolled in the control group, after exclusion of the skipped cases. The demographic data and the gestational age at the beginning of the study show insignificant differences. There were insignificant differences as regard the gestational age at which the pregnancy was terminated and fetal birth weight in patients with positive ACL test, positive LA test and positive B2 however the mean gestational age at which pregnancy was terminated was higher in study group. Also, there was insignificant difference as regards no of patients who complicated with abortion or who completed to full term. But had significant decrease number of case who complicated with preeclampsia (8, 21 patients in study and control group respectively). </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Intralipid infusion is a promising treatment option for control and prevention of problems caused by antiphospholipid antibody syndrome.</span></span>
文摘Background: Despite advances in revascularization and thrombolytic therapy, the outcome of patients after acute myocardial infarction (MI) could be complicated by ischemia reperfusion injury (IRI) and subsequent ventricular remodeling. Inflammation plays a central role in IRI. Intralipid<sup>®</sup> has been shown to reduce infarct size after IRI, but its effects on myocardial inflammation have not been addressed. The goal of this study is to investigate the effects of Intralipid<sup>®</sup> on in-situ myocardial inflammation and to better characterize its cardio-protective effects. Methods and Results: Cellular MRI was used to evaluate myocardial inflammation of iron-oxide-labeled macrophage infiltration. Cardiac MRI was used to evaluate global and regional ventricular wall motion, as well as myocardial perfusion and infarction in a rat model. Our results show that the Intralipid<sup>®</sup> treatment following IRI can preserve global and regional ventricular wall motion, and reduce the infarct size. The In-tralipid<sup>®</sup>-treated rats exhibit reduced myocardial macrophage infiltration, indicating reduced in-situ myocardial inflammation. Conclusions: Our results indicate that the Intralipid<sup>®</sup> treatment can protect the heart against IRI and can specifically reduce in-situ myocardial inflammation. Additional study is needed to assess if treatment using Intralipid<sup>®</sup> after LAD occlusion could improve the recovery of patients suffering from a heart attack and also reduce future development of heart failure.
基金supported by Science and Technology Planning Project of Hainan Province(No.20158328)
文摘Background The commonly used method so far for formulating hyperlipidemia animal models is to feed the animals with a high fat diet. Owning to influences of animal feeding, dosage and cycle, feeding with a high fat diet has resulted in an unstable quality. It is unknown whether gastric perfusion of intralipid can establish a better hyperlipidemia model in rabbits. Methods Twenty rabbits were randomly selected and subjected to gastric intralipid perfusion for consecutive 2 weeks or to feed with common high cholesterol feed for 4 weeks. The levels of blood serum total cholesterol （TC）, triglyceride （TG）, apolipoprotein A1 （APOA1）, APOB, blood plasma thromboxane B2 （TXB2）, 6-Keto-prostaglandin F1α （6-Keto-PGF1α）, endotheline （ET）, erythrocyte membrane cholesterol （M-Tc）, membrane fluidity （M-Flu）, erythrocyte malondialdehyde （E-MDA）, erythrocyte superoxide dismutase （E-SOD） before and after the experiment. In the end of the experiment, the aortae were removed from all the animals for light and electron microscopic examinations. Results The results showed that in both groups, the levels of blood serum TC, TG, APOB, blood plasma TXB2, ET, erythrocyte M-Flu and E-MDA were significantly increased. Blood serum APOA1, blood plasma 6-Keto-PGF1α and E-SOD were significantly decreased. But, erythrocyte M-TC had no significantly changed. The indexes of the two groups were no obvious difference before and after the experiment. Light and electron microscopic examination showed that there were early changes of early atherosclosis in the two groups of animal, in accordance with the characteristics of experimental animal hyperlipidemia. Conclusion The results suggest that gastric perfusion of intralipid can produce hyperlipidemia in rabbits faster than the commonly used model developed by feeding high cholesterol diet.
